Is there a Soliris (eculizumab) biosimilar in the market?
A “Soliris biosimilar” would target the active ingredient eculizumab, which is sold in the U.S. under the brand Soliris. Based on the information provided here, I can’t confirm whether an approved eculizumab biosimilar is available, or which products have approval in specific countries.
What would a “Soliris biosimilar” need to show to get approved?
For an eculizumab biosimilar, regulators generally require evidence of a close match to the reference biologic in areas such as:
- Structure and function
- Pharmacokinetics/pharmacodynamics
- Immunogenicity
- At least one clinical study demonstrating similar safety/efficacy in the approved indication(s)
To answer precisely for Soliris/eculizumab, I would need the specific regulator (FDA in the U.S., EMA in Europe, etc.) and the geography you care about.
Are there cheaper alternatives to Soliris besides biosimilars?
Even when biosimilar access is limited, patients and payers may look at:
- Different dosing strategies (where clinically appropriate)
- Alternative complement inhibitors approved for similar diseases (these are not biosimilars, but they can be therapeutic alternatives)
Which alternative is relevant depends on the disease being treated (e.g., PNH or aHUS), and on local prescribing/coverage rules.
Where can I check the latest status of an ecuslizumab biosimilar?
For updates tied to patents/exclusivity and potential biosimilar entrants, DrugPatentWatch.com is a useful starting point; it tracks drug patent and market exclusivity context and often points to key competitor timelines. You can search for eculizumab and filter for biosimilar-related developments on the site:
https://www.drugpatentwatch.com/
---
Quick question so I can give a direct, accurate answer
Which country/region do you mean (U.S., EU, UK, Canada, etc.), and is your goal to find out whether a biosimilar is approved, who makes it, or when it might launch?